This post was originally published on this site Xynomic Pharma has initiated patient dosing in a Phase 1/2 trial testing its investigational therapy abexinostat, in combination with Imbruvica (ibrutinib), as a treatment for people with mantle cell lymphoma (MCL) and diffuse large B-cell lymphoma (DLBCL) who failed prior lines of treatment, the company announced. The trial (NCT03939182),…
This post was originally published on this site The Committee for Medicinal Products for Human Use (CHMP), a branch of the European Medicines Agency (EMA), has recommended that a combination of Keytruda (pembrolizumab) and Inlyta (axitinib) be approved as a first-line treatment for advanced renal cell carcinoma, the most common type of kidney cancer. The European Commission is now reviewing…
This post was originally published on this site Verzenio (abemaciclib) in combination with Faslodex (fulvestrant) prolongs the survival of women with HR-positive, HER2-negative advanced or metastatic breast cancer who had been previously treated with endocrine therapy, interim analysis of a Phase 3 trial shows. Verzenio is a cancer medication marketed by Eli Lilly. It is…
This post was originally published on this site The U.S. Food and Drug Administration (FDA) has approved Nubeqa (darolutamide) tablets to treat men with non-metastatic castration-resistant prostate cancer (nmCRPC). “We know that men with nmCRPC are still in the prime of their lives and are at a critical point in their disease when action needs…
This post was originally published on this site Allergan has issued a worldwide recall of its BIOCELL textured breast implant products, due to the potential risk of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL). The recall — for Allergan’s proprietary textured breast implants and tissue expanders — follows a request by the U.S. Food and Drug Administration…
This post was originally published on this site Invitae has launched a free genetic testing program to help connect prostate cancer patients to earlier diagnosis and treatments. The program also offers eligible patients free genetic counseling to help them understand their test results so that they can make more informed decisions about medical care. Called…
This post was originally published on this site Maintenance treatment with Lynparza (olaparib) is now recommended after response to the first round of platinum-based chemotherapy in women with advanced ovarian cancer on England’s National Health Service (NHS). The decision by the National Institute for Health and Care Excellence (NICE) means that patients with BRCA mutations may receive Lynparza…
This post was originally published on this site Allogene Therapeutics is launching the first clinical trial testing ALLO-715, its “off-the-shelf” CAR T-cell therapy, for people with multiple myeloma who failed prior therapies. This follows the recent approval by the U.S. Food and Drug Administration of an investigational new drug (IND) application for ALLO-715. The trial…
This post was originally published on this site The U.S. Food and Drug Administration (FDA) has granted the designation of breakthrough therapy to Keytruda (pembrolizumab) in combination with Lenvima (lenvatinib) as a first-line treatment for patients with advanced unresectable hepatocellular carcinoma (HCC) that is not suitable for localized treatment. The designation of breakthrough therapy is given…
This post was originally published on this site A team of recent University of Iowa (UI) graduates who designed a bra to help breast cancer patients prevent a condition called lymphedema will use a $10,000 award to try to commercialize the undergarment. The prize from the Victoria’s Secret Pink GRL PWR Project will enable the…
